James M. Mock - 28 Feb 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Financial Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 16:29:38 UTC
Previous filing
07 Oct 2022
Next filing
10 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +20,040 $0.000000 20,040 28 Feb 2023 Common Stock 20,040 $138.81 Direct F1
transaction MRNA Restricted Stock Units Award $0 +5,260 $0.000000 5,260 28 Feb 2023 Common Stock 5,260 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.